Medtronic plc.

As of July 31, 2026, Medtronic PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh carries a market capitalization of 559.09B, placing it among publicly traded companies globally. Its enterprise value stands at 660.42B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Medtronic PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh's next confirmed earnings release is scheduled for November 24, 2026.

As of July 31, 2026, Medtronic PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh has 10.26B shares outstanding.

As of July 31, 2026, Medtronic PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh trades at a trailing price-to-earnings ratio of 21.07. The price-to-sales ratio is 2.94, and the price-to-book ratio stands at 2.19.

As of July 31, 2026, Medtronic PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh trades at an EV/EBITDA multiple of 13.37 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.46 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 19.16 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Medtronic PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh trades at an EV/FCF ratio of 19.38, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 660.42B versus a market cap of 559.09B, with the gap driven by net debt and cash on the balance sheet.

As of July 31, 2026, Medtronic PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh maintains a current ratio of 2.07, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 55.36, indicating elevated leverage, while an interest coverage ratio of 13.43 demonstrates strong ability to service its debt obligations.

Over the twelve months ended July 31, 2026, Medtronic PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh posted a return on equity (ROE) of 10.66, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.89 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 5.68, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.41, useful for judging operating efficiency across full business cycles. The company generates approximately 2.01M in revenue per employee across its workforce of 95,000.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.17 indicates how many times Medtronic PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended July 31, 2026, Medtronic PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh recorded 6.77B in income tax expense. That works out to an effective tax rate of 20.18, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 33.54B, leaving 26.57B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Medtronic PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh's stock has declined approximately 6.49% over the past 52 weeks. The 50-day moving average sits at 57.57, while the 200-day moving average is 59.50.

Over the twelve months ended July 31, 2026, Medtronic PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh generated 190.67B in revenue and converted that into 26.57B in net income, yielding earnings per share of 2.59. EBITDA reached 49.40B, while operating income came in at 36.30B.

As of July 31, 2026, Medtronic PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh holds 44.79B in cash and equivalents against 142.99B in total debt, resulting in a net debt position of 134.13B. Total book value stands at 255.12B, with working capital of 63.95B providing operational flexibility.

Medtronic PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh produced 40.81B in operating cash flow over the twelve months ended July 31, 2026. After subtracting -9.67B in capital expenditures, free cash flow totaled 31.14B - equivalent to 3.03 per share.

Over the twelve months ended July 31, 2026, Medtronic PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh posted a gross margin of 65.01, reflecting its pricing power and cost economics. The operating margin of 19.04 and net profit margin of 13.93 provide insight into operational efficiency.

Over the twelve months ended July 31, 2026, Medtronic PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh paid dividends of 1.81 per share. The dividend payout ratio of 68.78 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 5.54, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.37, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Medtronic PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh shareholders.

Medtronic PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh's most recent stock split took place on July 29, 2026 with a 1:4 split ratio.

As of July 31, 2026, Medtronic PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh has an Altman Z-Score of 4.63, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.